ContraFect Corporation Adds Former Cubist Executive Steven C. Gilman, PhD, to Board of Directors as Executive Chairman May 20, 2015
ContraFect Corporation Announces Commencement of Phase 1 Clinical Trial of CF-301 for Staph Bloodstream Infections, Including MRSA April 29, 2015
ContraFect to Present Company Overview, Including Clinical Plan for CF-301, at the 7th Annual Biotech Showcase January 7, 2015
ContraFect Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections December 22, 2014
